Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database

Cephalalgia

Volumn 28, Issue 1, 2008, Pages 35-40

  Diener, H C ^a   Dodick, D W ^b   Goadsby, P J ^c   Lipton, R B ^d   Almas, M ^e   Parsons, B ^e  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MAYO CLINIC   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e Pfizer Global Pharmaceuticals   (United States)

Author keywords

Eletriptan; Migraine; Risk factors; Sumatriptan; Triptans

Indexed keywords

ELETRIPTAN; PLACEBO; SUMATRIPTAN;

ANALGESIA; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG TREATMENT FAILURE; HUMAN; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHONOPHOBIA; PHOTOPHOBIA; RISK FACTOR; TREATMENT OUTCOME;

EID: 36749093479     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2007.01457.x     Document Type: Article

References (27)

1. Pascual J. New perspectives in migraine treatment: how to treat the difficult migraine patient. Neurologia 2004 19 (Suppl. 2 1 7.
2. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002 22 : 633 58.
3. Goldstein J, Tiseo PJ, Albert KS, Li C, Sykes CR. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache 2006 46 : 1142 50.
4. Färkkilä M, Olesen J, Dahlöf C, Stovner LJ, ter Bruggen JP, Rasmussen S et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003 23 : 463 71.
5. Mathew NT, Kailasam J, Gentry P, Chernyshev O. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache 2000 40 : 464 5.
6. Stark SR, Spierings EL, McNeal S, Putnam DG, Bolden-Watson CP, O'Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000 40 : 513 20.
7. Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Eur Neurol 2005 53 (Suppl. 1 41 8.
8. Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache 2005 45 : 162.
9. Sheftell FD, Feleppa M, Tepper S, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 2004 44 : 668.
10. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002 58 : 885 94.
11. Goadsby PJ, Dodick DW, Ferrari MD, McCrory DC, Williams P. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neurol Scand 2004 110 : 137 43.
12. Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002 97 : 247 57.
13. Diener HC, Ferrari M, Mansbach H, SNAP Database Study Group. Predicting the response to sumatriptan. Neurology 2004 63 : 524.
14. ®) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002 47 : 99 107.
15. Garcia-Ramos G, MacGregor EA, Hilliard B, Bordini CA, Leston J, Hettiarachchi J. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 2003 23 : 869 76.
16. Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM, Jackson NC et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 2000 54 : 156 63.
17. Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 2003 43 : 962 74.
18. Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003 43 : 214 22.
19. Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002 59 : 1210 7.
20. Sheftell F, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 2003 43 : 202 13.
21. Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirheads N, Sikes CR. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003 23 : 942 52.
22. Stark SR, Dahlöf C, Haughie S, Hettiarachchi J, Eletriptan Steering Committee. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002 22 : 23 32.
23. Headache Classification Committee of the International Headache Society. Classification and diagnosis criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988 8 (Suppl. 7 1 96.
24. International Conference on Harmonization. Guidance for industry. E6 good clinical practice: consolidated guidance. 1996. Available at http://www.fda.gov/cder/guidance/959fnl.pdf Last accessed June 2006.
25. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000 123 : 1703 9.
26. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005 25 : 735 42.
27. Martin V, Valade D, Almas M, Hettiarachchi J, Sikes C, Albert KS et al. Efficacy of eletriptan in triptan-naive patients: results of a combined analysis. Headache 2007 47 : 181 8.